ZA201000151B - Pyridone gpr119 g protein-coupled receptor agonists - Google Patents

Pyridone gpr119 g protein-coupled receptor agonists

Info

Publication number
ZA201000151B
ZA201000151B ZA2010/00151A ZA201000151A ZA201000151B ZA 201000151 B ZA201000151 B ZA 201000151B ZA 2010/00151 A ZA2010/00151 A ZA 2010/00151A ZA 201000151 A ZA201000151 A ZA 201000151A ZA 201000151 B ZA201000151 B ZA 201000151B
Authority
ZA
South Africa
Prior art keywords
gpr119
pyridone
protein
receptor agonists
coupled receptor
Prior art date
Application number
ZA2010/00151A
Other languages
English (en)
Inventor
Dean A Wacker
Karen A Rossi
Ying Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA201000151B publication Critical patent/ZA201000151B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
ZA2010/00151A 2007-07-17 2010-01-08 Pyridone gpr119 g protein-coupled receptor agonists ZA201000151B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95016207P 2007-07-17 2007-07-17
PCT/US2008/070101 WO2009012275A1 (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists

Publications (1)

Publication Number Publication Date
ZA201000151B true ZA201000151B (en) 2011-03-30

Family

ID=39864683

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2010/00151A ZA201000151B (en) 2007-07-17 2010-01-08 Pyridone gpr119 g protein-coupled receptor agonists
ZA2010/00326A ZA201000326B (en) 2007-07-17 2010-01-15 Methods for modulating gpr119 g protein-coupled receptor and selected compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2010/00326A ZA201000326B (en) 2007-07-17 2010-01-15 Methods for modulating gpr119 g protein-coupled receptor and selected compounds

Country Status (26)

Country Link
US (6) US7928230B2 (enExample)
EP (2) EP2170864B1 (enExample)
JP (3) JP5301539B2 (enExample)
KR (2) KR20100045471A (enExample)
CN (3) CN103550218A (enExample)
AR (2) AR067569A1 (enExample)
AT (2) ATE524460T1 (enExample)
AU (2) AU2008276055B2 (enExample)
BR (2) BRPI0814428A2 (enExample)
CA (2) CA2693439A1 (enExample)
CL (2) CL2008002110A1 (enExample)
CO (1) CO6160315A2 (enExample)
CY (2) CY1112151T1 (enExample)
DK (2) DK2173737T3 (enExample)
EA (2) EA018709B1 (enExample)
ES (2) ES2371515T3 (enExample)
HR (2) HRP20110806T1 (enExample)
IL (1) IL228120A0 (enExample)
NZ (2) NZ582661A (enExample)
PE (2) PE20090888A1 (enExample)
PL (2) PL2170864T3 (enExample)
PT (2) PT2173737E (enExample)
SI (2) SI2170864T1 (enExample)
TW (2) TW200904440A (enExample)
WO (2) WO2009012277A1 (enExample)
ZA (2) ZA201000151B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005310467B2 (en) * 2004-12-01 2011-06-23 Msd K.K. Substituted pyridone derivative
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
EP2170864B1 (en) 2007-07-17 2011-09-14 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
AU2009270984A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and methods of use thereof
CN102159572A (zh) * 2008-07-16 2011-08-17 ć…ˆç”ć…Źćž ćŒçŽŻæ‚çŽŻèĄç”Ÿç‰©ćŠć…¶äœœäžșgpr 119è°ƒèŠ‚ć‰‚çš„ç”šé€”
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
EP2408780A2 (en) * 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloĂœ3.3.1šnonanes
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
EP2445901A1 (en) 2009-06-24 2012-05-02 Boehringer Ingelheim International GmbH New compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ăƒ™ăƒŒăƒȘăƒłă‚ŹăƒŒ ă‚€ăƒłă‚Čăƒ«ăƒă‚€ăƒ  ă‚€ăƒłă‚żăƒŒăƒŠă‚·ăƒ§ăƒŠăƒ« ă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ ミット ăƒ™ă‚·ăƒ„ăƒŹăƒłă‚Żăƒ†ăƒ« ハフツング çł–ć°żç—…ćŠăłé–ąé€ŁçŠ¶æ…‹ăźæČ»ç™‚ă§ç”šă„ă‚‹ïœ‡ïœïœ’ïŒ‘ïŒ‘ïŒ™äœœć‹•è–Źăšïœ„ïœ„ïœâˆ’ïœ‰ïœ–é˜»ćźłè–ŹăƒȘナグăƒȘăƒ—ăƒăƒłăźç”„ćˆă›
BR112012025590A2 (pt) 2010-04-08 2016-06-21 Bristol Myers Squibb Co anĂĄlogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
EA201270778A1 (ru) 2010-05-06 2013-04-30 Đ‘Ń€ĐžŃŃ‚ĐŸĐ»-МаĐčДрс ĐĄĐșĐČОбб ĐšĐŸĐŒĐżĐ°ĐœĐž БоцоĐșлОчДсĐșОД ĐłĐ”Ń‚Đ”Ń€ĐŸĐ°Ń€ĐžĐ»ŃŒĐœŃ‹Đ” Đ°ĐœĐ°Đ»ĐŸĐłĐž ĐČ ĐșачДстĐČĐ” ĐŒĐŸĐŽŃƒĐ»ŃŃ‚ĐŸŃ€ĐŸĐČ Ń€Đ”Ń†Đ”ĐżŃ‚ĐŸŃ€Đ° gpr119
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
PH12013500671A1 (en) 2010-10-08 2018-04-11 Cadila Healthcare Ltd Novel gpr 119 agonists
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
EP2648516B1 (en) 2010-12-06 2018-09-05 Aclaris Therapeutics, Inc. Substituted pyridinone-pyridinyl compounds
WO2012123449A1 (en) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9695148B2 (en) * 2012-11-13 2017-07-04 Nissan Chemical Industries, Ltd. 2-pyridone compound
CN102993088A (zh) * 2012-12-31 2013-03-27 äžœćŽć€§ć­Š 侀种4-矟ćŸș-2-ćĄć•¶é…źçš„ćˆ¶ć€‡æ–čæł•
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv ç¶“ć–ä»Łçš„7-æ°źé›œé›™ç’°éĄžćŠć…¶äœœç‚șéŁŸæ…Ÿæż€çŽ ć—é«”èȘżçŻ€ćŠ‘äč‹ç”šé€”
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv ç¶“ć–ä»Łäč‹ć“Œć•¶ćŒ–ćˆç‰©ćŠć…¶äœœç‚șéŁŸæ…ŸçŽ ć—é«”èȘżçŻ€ćŠ‘äč‹ç”šé€”
TWI621618B (zh) 2013-03-13 2018-04-21 æŻ”ćˆ©æ™‚ć•†ć„ç”Ÿè—„ć“ć…Źćž ç¶“ć–ä»ŁïŒ’ïŒæ°źé›œé›™ç’°éĄžćŠć…¶äœœç‚șéŁŸæ…ŸçŽ ć—é«”èȘżæŽ§ćŠ‘äč‹ç”šé€”
JP6699909B2 (ja) 2013-06-07 2020-05-27 ă‚ąă‚Żăƒ©ăƒȘă‚č ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ăƒĄăƒăƒ«ïŒăƒ•ăƒ«ă‚Șロ−ピăƒȘă‚žăƒ‹ăƒ«âˆ’ăƒĄăƒˆă‚­ă‚·çœźæ›ăƒ”ăƒȘゾノン−ピăƒȘă‚žăƒ‹ăƒ«ćŒ–ćˆç‰©ćŠăłăƒ•ăƒ«ă‚Șロ−ピăƒȘăƒŸă‚žăƒ‹ăƒ«âˆ’ăƒĄăƒˆă‚­ă‚·çœźæ›ăƒ”ăƒȘゾノン−ピăƒȘă‚žăƒ‹ăƒ«ćŒ–ćˆç‰©
WO2014202510A1 (de) 2013-06-20 2014-12-24 Bayer Cropscience Ag Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
BR112015031155A2 (pt) 2013-06-20 2017-07-25 Bayer Cropscience Ag derivados de sulfureto de arila e derivados de aril sulfĂłxido como acaricidas e inseticidas
ES2728531T3 (es) 2013-07-08 2019-10-25 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfĂłxido de seis miembros enlazados con C-N como agentes para combatir parĂĄsitos
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
US9611262B2 (en) 2014-09-11 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016130652A1 (en) 2015-02-10 2016-08-18 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) * 2015-03-25 2019-09-18 慬益èČĄć›Łæł•äșșç›žæšĄäž­ć€źćŒ–ć­Šç ”ç©¶æ‰€ äž€çœźæ›ïŒˆăƒ•ăƒ«ă‚Șăƒ­ă‚ąăƒ«ă‚­ăƒ«ïŒ‰ă‚šăƒăƒŹăƒłéĄžćŠăłăăźèŁœé€ æ–čæł•
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
CN115667277A (zh) 2020-02-28 2023-01-31 ćĄć°”äŒ˜æ™źć…Źćž Gpr40æż€ćŠšć‰‚
PH12022552263A1 (en) 2020-03-27 2023-11-13 Aclaris Therapeutics Inc Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) * 2022-08-15 2022-12-23 ćčżè„żäž­ćŒ»èŻć€§ć­Š 4-ç”ČćŸș-2-ćŻčç”Čè‹ŻćŸș-6-矰ćŸș搥敶-3-ç”Čé…žćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) * 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as ÎČ3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid ÎČ3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine ÎČ 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as ÎČ3 agonists
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 ПфаĐčзДр ĐŸŃ€ĐŸĐŽĐ°Đșтс Đ†ĐœĐș. Đ€Đ°Ń€ĐŒĐ°Ń†Đ”ĐČŃ‚ĐžŃ‡ĐœĐ° ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†Ń–Ń, Ń‰ĐŸ ĐŒŃ–ŃŃ‚ĐžŃ‚ŃŒ Ń–ĐœĐłŃ–Đ±Ń–Ń‚ĐŸŃ€ Đ°Đ»ŃŒĐŽĐŸĐ·ĐŸŃ€Đ”ĐŽŃƒĐșŃ‚Đ°Đ·Đž та Ń–ĐœĐłŃ–Đ±Ń–Ń‚ĐŸŃ€ гліĐșĐŸĐłĐ”ĐœŃ„ĐŸŃŃ„ĐŸŃ€ĐžĐ»Đ°Đ·Đž (ĐČĐ°Ń€Ń–Đ°ĐœŃ‚Đž), ĐșĐŸĐŒĐżĐ»Đ”Đșт, яĐșĐžĐč її ĐČĐșлючає, та ŃĐżĐŸŃĐŸĐ±Đž ліĐșуĐČĐ°ĐœĐœŃ ссаĐČціĐČ Đ·Ń– ŃŃ‚Đ°ĐœĐŸĐŒ Ń–ĐœŃŃƒĐ»Ń–ĐœĐŸŃ€Đ”Đ·ĐžŃŃ‚Đ”ĐœŃ‚ĐœĐŸŃŃ‚Ń–
EE200100006A (et) 1998-07-06 2002-06-17 Bristol-Myers Squibb Company BifenĂŒĂŒlsulfoonamiidid kui duaalse angiotensiin-endoteliini retseptori antagonistid
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
US6586418B2 (en) 2000-06-29 2003-07-01 Bristol-Myers Squibb Company Thrombin or factor Xa inhibitors
WO2002044362A1 (en) 2000-12-01 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for diabetes
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
JP4164031B2 (ja) * 2002-02-14 2008-10-08 ăƒ•ă‚Ąăƒ«ăƒžă‚·ă‚ą ă‚łăƒŒăƒăƒŹăƒŒă‚·ăƒ§ăƒł ïŒ°ïŒ“ïŒ˜ïœïœïœă‚­ăƒŠăƒŒă‚Œăźăƒąă‚žăƒ„ăƒŹăƒŒă‚żăšă—ăŠăźçœźæ›ă•ă‚ŒăŸăƒ”ăƒȘゾノン
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
ES2316964T3 (es) 2003-02-24 2009-04-16 Arena Pharmaceuticals, Inc. Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa.
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7003597B2 (en) * 2003-07-09 2006-02-21 International Business Machines Corporation Dynamic reallocation of data stored in buffers based on packet size
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN100509798C (zh) * 2003-07-11 2009-07-08 è‰Ÿć°Œçșłćˆ¶èŻć…Źćž 䜜äžșæ–°é™ˆä»Łè°ąè°ƒèŠ‚ć‰‚çš„äž‰ć–ä»ŁèŠłćŸșć’Œæ‚èŠłćŸșèĄç”Ÿç‰©ä»„ćŠéą„é˜Č撌æȻ疗䞎慶盞慳äč‹ç—…ç—‡
EA010023B1 (ru) * 2003-07-14 2008-06-30 ĐŃ€Đ”ĐœĐ° Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз, Đ˜ĐœĐș. ĐšĐŸĐœĐŽĐ”ĐœŃĐžŃ€ĐŸĐČĐ°ĐœĐœŃ‹Đ” Đ°Ń€ĐžĐ»ŃŒĐœŃ‹Đ” Đž ĐłĐ”Ń‚Đ”Ń€ĐŸĐ°Ń€ĐžĐ»ŃŒĐœŃ‹Đ” ĐżŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Đ” ĐČ ĐșачДстĐČĐ” ĐŒĐŸĐŽŃƒĐ»ŃŃ‚ĐŸŃ€ĐŸĐČ ĐŒĐ”Ń‚Đ°Đ±ĐŸĐ»ĐžĐ·ĐŒĐ° Đž ĐŽĐ»Ń ĐżŃ€ĐŸŃ„ĐžĐ»Đ°ĐșтоĐșĐž Đž Đ»Đ”Ń‡Đ”ĐœĐžŃ Ń€Đ°ŃŃŃ‚Ń€ĐŸĐčстĐČ, сĐČŃĐ·Đ°ĐœĐœŃ‹Ń… с ĐœĐ°Ń€ŃƒŃˆĐ”ĐœĐžĐ”ĐŒ ĐŒĐ”Ń‚Đ°Đ±ĐŸĐ»ĐžĐ·ĐŒĐ°
WO2005025504A2 (en) 2003-09-12 2005-03-24 Kemia, Inc. Modulators of calcitonin and amylin activity
US7732456B2 (en) * 2004-03-05 2010-06-08 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
BRPI0508935A (pt) 2004-03-17 2007-09-25 7Tm Pharmas As agonistas de receptor seletivo y4 para intervençÔes terapĂȘuticas
DE602005015962D1 (de) * 2004-05-03 2009-09-24 Hoffmann La Roche Indolylderivate als liver-x-rezeptormodulatoren
WO2005121121A2 (en) 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20060292073A1 (en) * 2005-06-23 2006-12-28 Emory University Stereoselective Synthesis of Amino Acid Analogs for Tumor Imaging
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP1907383A1 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
JP2010526146A (ja) 2007-05-04 2010-07-29 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ −äșŒç’°ćŒïœ‡ïœïœ’ïŒ‘ïŒ‘ïŒ™ïœ‡ă‚żăƒłăƒ‘ă‚ŻèłȘç”ćˆć—ćźčäœ“ă‚ąă‚Žăƒ‹ă‚čト
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
EP2170864B1 (en) * 2007-07-17 2011-09-14 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists

Also Published As

Publication number Publication date
US8003796B2 (en) 2011-08-23
CA2693444A1 (en) 2009-01-22
US20120232048A1 (en) 2012-09-13
JP2010533727A (ja) 2010-10-28
JP2013237680A (ja) 2013-11-28
DK2173737T3 (da) 2012-05-07
AR067568A1 (es) 2009-10-14
WO2009012277A1 (en) 2009-01-22
EP2173737A1 (en) 2010-04-14
EP2170864A1 (en) 2010-04-07
BRPI0814428A2 (pt) 2015-01-06
IL228120A0 (en) 2013-09-30
CY1112151T1 (el) 2015-12-09
ES2371515T3 (es) 2012-01-04
WO2009012275A1 (en) 2009-01-22
CL2008002110A1 (es) 2008-10-24
AU2008276057B2 (en) 2013-01-31
US20120258959A1 (en) 2012-10-11
PE20090449A1 (es) 2009-04-18
EA201000210A1 (ru) 2010-06-30
CA2693439A1 (en) 2009-01-22
US20090042919A1 (en) 2009-02-12
JP2010533726A (ja) 2010-10-28
SI2170864T1 (sl) 2012-04-30
ES2378914T3 (es) 2012-04-19
US8178561B2 (en) 2012-05-15
HK1136298A1 (en) 2010-06-25
EA201000211A1 (ru) 2010-06-30
US7928230B2 (en) 2011-04-19
CN101801956B (zh) 2013-11-20
KR20100045471A (ko) 2010-05-03
TW200904440A (en) 2009-02-01
AR067569A1 (es) 2009-10-14
ATE540945T1 (de) 2012-01-15
HK1143136A1 (en) 2010-12-24
NZ582664A (en) 2012-03-30
EP2173737B1 (en) 2012-01-11
ZA201000326B (en) 2011-03-30
EA016595B1 (ru) 2012-06-29
US8232404B2 (en) 2012-07-31
JP5318867B2 (ja) 2013-10-16
AU2008276057A1 (en) 2009-01-22
ATE524460T1 (de) 2011-09-15
PL2170864T3 (pl) 2012-02-29
BRPI0815097A2 (pt) 2018-07-24
CN101801956A (zh) 2010-08-11
AU2008276055B2 (en) 2013-01-31
CN103550218A (zh) 2014-02-05
US8513424B2 (en) 2013-08-20
PT2173737E (pt) 2012-03-19
PL2173737T3 (pl) 2012-06-29
DK2170864T3 (da) 2012-01-16
HRP20120221T1 (hr) 2012-04-30
US20090023702A1 (en) 2009-01-22
US20110190327A1 (en) 2011-08-04
SI2173737T1 (sl) 2012-05-31
EP2170864B1 (en) 2011-09-14
HRP20110806T1 (hr) 2011-11-30
US20110245227A1 (en) 2011-10-06
CY1112751T1 (el) 2016-02-10
PT2170864E (pt) 2011-11-25
WO2009012275A9 (en) 2010-03-11
TW200904439A (en) 2009-02-01
CN101801957A (zh) 2010-08-11
KR20100051814A (ko) 2010-05-18
CO6160315A2 (es) 2010-05-20
PE20090888A1 (es) 2009-07-15
EA018709B1 (ru) 2013-10-30
NZ582661A (en) 2012-03-30
AU2008276055A1 (en) 2009-01-22
CL2008002111A1 (es) 2008-10-24
JP5301539B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
ZA201000151B (en) Pyridone gpr119 g protein-coupled receptor agonists
IL208919A0 (en) Gpr119 receptor agonists
EP2173174A4 (en) FARNESOID X RECEPTOR AGONISTS
EP2170072A4 (en) Farnesoid X RECEPTOR AGONISTS
GB0720390D0 (en) G-Protein coupled receptor agonists
GB0720389D0 (en) G-Protein Coupled Receptor Agonists
GB0607196D0 (en) G-protein coupled receptor agonists
AP2010005267A0 (en) Novel glucocorticoid receptor agonists
PL2114931T3 (pl) Piperydynowe agonisty GPCR
PL2114935T3 (pl) Piperydynowi agoniƛci GPCR
EP2041120A4 (en) MELANOCORTIN RECEPTOR AGONISTS
EP2311822A4 (en) GPR119 AGONIST
IL212468A0 (en) Melanocortin receptor agonists
PT1981902E (pt) Antagonistas dos recetores nogo
EP2474540A4 (en) GPR119 AGONIST
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
IL198650A0 (en) Progesterone receptor antagonists
IL212545A0 (en) Toll-like receptor 3 antagonists
IL210773A0 (en) Neuropeptide-2 receptor (y-2r) agonists and uses thereof
EP2017281A4 (en) AGONISTS AT TOLL-LIKE RECEPTOR 9
EP2153736A4 (en) NEW LEUKOTRIEN RECEPTOR ANTAGONIST
ZA201005826B (en) Selective agonist of toll-like receptor 3
IL202454A0 (en) Urotensin ii receptor antagonists
GB0720388D0 (en) G-protein coupled receptor agonists
ZA201103984B (en) Toll-like receptor 3 antagonists